Navigation Links
Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA
Date:9/24/2007

BASEL, Switzerland, September 24 /PRNewswire/ -- Nitec Pharma AG today announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application submitted by Nitec for the initiation of clinical development for Lodotra.

Following the positive results of a European Phase III trial (CAPRA-1; Circadian Administration of Prednisone in Rheumatoid Arthritis), Nitec submitted a dossier for marketing authorization in Europe. The FDA's acceptance of the IND will now allow Nitec to start clinical development of Lodotra in the USA.

A second Phase III study (CAPRA-2), currently planned to be initiated in the second quarter of 2008 will include about 300 patients in the US and EU.

"The new Lodotra trial is highly relevant for rheumatoid arthritis patients. Lodotra reduces IL-6 levels and has great potential to improve the signs and symptoms of RA, such as morning stiffness," commented Professor Kenneth G. Saag of the University of Alabama at Birmingham, member of the scientific steering group in the planned Phase III trial.

Clinical trials of Lodotra have demonstrated that it is a treatment that can make a difference to the lives of patients with RA. Morning stiffness is a debilitating symptom of the disease with a significant negative impact on the lives of patients with RA and Lodotra now offer clinicians an effective potential treatment option.

"It was always our intention to conduct the appropriate trials in the US and to further elucidate the additional benefits which Lodotra can bring to RA patients on top of the exciting results we have seen in our CAPRA-1 study. We are therefore very pleased to have been given the go-ahead from the FDA to initiate the clinical development of Lodotra in the USA," said Anders Harfstrand, CEO of Nitec Pharma.

Lodotra is a modified-release tablet that has been developed to optimize the efficacy of orally administered low-dose prednisone in Rheumatoid Arthri
'/>"/>

SOURCE Nitec Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. A Versatile Power Supply for All Electrophoresis Applications
2. Highest Possible Transformation Efficiencies for High-Throughput Applications
3. Unique DNA Polymerase Formulation Excels in a Broad Range of PCR Applications
4. High-Throughput System Generates Ultra-Pure PCR Products Suitable for All Applications
5. An Assessment of the Eppendorf twin.tec plate performance in PCR* applications
6. Principles and applications of electrical cell fusion
7. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
8. Optimizing Büchi® Rotary Evaporator Applications
9. Principles and applications of electrical cell fusion
10. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
11. Optimizing Büchi® Rotary Evaporator Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
(Date:7/29/2015)... , July 29, 2015 US-Australian drug discovery ... today confirmed it is committed to progressing its ground-breaking ... as practicable and to ensure the Company delivers the ... Officer, Iain Ross , said the Company currently ... lead pre-clinical programs, discovery programs and academic partnerships and ...
(Date:7/29/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today announced ... Officer has resigned.  The Company has hired Andrew ... in December 2014, as full time interim CFO and ... Andy Ashworth began his employment today, ... transition.  Andy was the Company,s CFO from September 2011 ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... March 7, 2012 Karyopharm Therapeutics Inc., a leader ... nine presentations covering its Selective Inhibitors of Nuclear Export ... meeting on March 31 – April 4, 2012, in ... studying the use of Karyopharm,s novel SINE, along with ...
... Inc. (OTC/BB: PROT) announced today that it has ... to which the Company has agreed to sell shares ... aggregate purchase price of approximately $3.8 million (which are ... common stock) and Series A, Series B and Series ...
... NEW YORK, March 5, 2012  Organovo, Inc., (OTCQB: ... on using its breakthrough NovoGen 3D human tissue ... research and medical applications, today announced that their ... on-demand viewing. LINK:    www.retailinvestorconferences.com ...
Cached Biology Technology:Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting 2Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting 3Proteonomix Announces a Private Placement of $3.8 Million 2Proteonomix Announces a Private Placement of $3.8 Million 3Proteonomix Announces a Private Placement of $3.8 Million 4Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... can lead to cellular changes in the cervix that ... of these pre-stages gives an increased risk of preterm ... pre-stages of cervical cancer, it may therefore reduce the ... calculated the benefits of HPV-vaccination. Cervical cancer ...
... Alexandria, Va. The 2009 Wilmer Souder Award is ... of,Colorado, Aurora, USA. The International Association for Dental Research ... & Exhibition in Miami, Florida, USA, on April 1, ... of Craniofacial Biology at the University of Colorado School ...
... of The Proceedings of the National Academy of Sciences ... "alpha-synuclein dance" the switching back and forth of the ... the surface that it is binding to changes. Such ... like alpha-synuclein, which are known to be unfolded in isolation, ...
Cached Biology News:HPV vaccine may prevent preterm births 2Scripps research scientists 'watch' as individual alpha-synuclein proteins change shape 2Scripps research scientists 'watch' as individual alpha-synuclein proteins change shape 3
... different Cynomolgus monkey normal tissues are ... upon request. Customers can choose ... set, and pay 70% of the ... P Set products are for research ...
...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
cysteine and glycine-rich protein 2,...
Biology Products: